Early Detection of Pancreatic Adenocarcinoma Using ImmunoPET, Hyperpolarized Pyruvate MRI, and Blood Tests in Patients with High-Risk Pancreatic Cysts

What this Trial Is About

Researchers are studying ways to detect pancreatic ductal adenocarcinoma PDAC early in patients with pancreatic cysts to avoid invasive surgery. They believe that combining special imaging techniques with blood tests may help identify PDAC at an early stage. This observational study focuses on patients with high-risk pancreatic cystic neoplasms who require surgical removal. Participants may undergo an ImmunoPET scan using the imaging agent 89Zr-DFO-HuMab-5B1 and a hyperpolarized pyruvate magnetic resonance imaging HP MRI scan before surgery. Blood samples will be collected within six weeks before surgery and then annually after surgery as part of post-operative care. These tests are being evaluated to find the best combination for detecting PDAC early. During the study, participants will have imaging scans and blood tests to monitor their pancreatic cysts. Researchers will assess the sensitivity of the ImmunoPET scan to detect the presence or absence of adenocarcinoma over one year. The study includes monitoring of liver, kidney, and heart functions to ensure participant safety. The total duration and follow-up depend on the participants surgery and post-operative care schedule.

Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms